BioSpace News Archive

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million compared to revenue of $206.7 million for the same period of fiscal 2020, driven by a record number of patients supported.

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases, announced today that it will hold a conference call and webcast on Wednesday, May 12, 2021 at 8:00 a.m. ET to discuss the company’s first quarter 2021 financial and operational results.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 6, 2021 to report financial results for the quarter ended March 31, 2021 and discuss recent business highlights.

− Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Advanced Vutrisiran toward Market with Positive Results from HELIOS-A Phase 3 Study and Submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA) –

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 Healthcare Conference.

The two leading global therapy areas — oncology and immunology — are forecast to grow 9-12% CAGR through 2025, lifted by significant increases in new treatments and medicine use

Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region.

BioVentrix, Inc ., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, May 6, 2021 at 8:30 a.m. EDT to report financial results for the first quarter 2021 and provide business updates.

Labcorp (NYSE: LH), a leading life sciences company, today announced results for the first quarter ended March 31, 2021 and raised 2021 guidance.